Full-Time

Manager – Clinical Quality

Posted on 2/19/2025

Arcellx

Arcellx

51-200 employees

Develops immunotherapies for cell therapy

Biotechnology
Healthcare

Compensation Overview

$140k - $180kAnnually

+ Bonus + Equity Grant

Senior, Expert

San Carlos, CA, USA

The job is onsite in Redwood City, CA.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Google Cloud Platform

You match the following Arcellx's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Bachelor’s degree and 8+ years’ experience working within GCP in a pharmaceutical or biologics environment.
  • Experience in Clinical Quality in a related industry (i.e. medical device or diagnostics) will be considered.
  • Experience implementing and integrating clinical quality systems in CBER regulated biotechnology companies.
  • Knowledge of applicable GCP regulations and industry guidance.
  • Demonstrated ability to assess risk and prioritize effectively, with the ability to work with aggressive timeframes and adhere to project deadlines in a fast-paced environment.
  • Strong communication and presentation skills with good relationship-building.
  • Ability to travel up to 20% of time.
Responsibilities
  • Act as a Clinical Quality lead by supporting study team compliance with national and international regulatory standards and guidance for cell therapy products.
  • Develop audit plans and audit strategy for ongoing clinical trials.
  • Perform initial and ongoing audit of clinical vendors.
  • Coordinate, plan and conduct internal system audits and external investigative site/vendor audits in accordance with Good Clinical Practice (GCP) guidelines.
  • Report audit findings to management with recommendations for resolution and verify appropriate corrective actions have been implemented/documented.
  • Participate in the development of clinical standard operating procedures, work instructions, forms, and templates.
  • Develop and conduct training for staff (GCP, Inspection Readiness training, etc.).
  • Support preparation for and execution of regulatory inspections.
  • Provide quality and regulatory compliance guidance to clinical colleagues.

Arcellx develops immunotherapies aimed at improving cell therapy for serious diseases. Their products focus on advanced techniques that enhance the effectiveness of treatments. The company collaborates with healthcare providers and research institutions to bring these therapies to patients. Unlike many competitors, Arcellx emphasizes proprietary immunotherapy products and has a business model that includes research, development, and commercialization, generating revenue through partnerships and licensing agreements. The main goal of Arcellx is to meet unmet medical needs by creating safe and effective treatment options.

Company Size

51-200

Company Stage

IPO

Total Funding

$194.5M

Headquarters

Gaithersburg, Maryland

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Growing investment in personalized medicine aligns with Arcellx's tailored immunotherapies.
  • Advancements in gene editing like CRISPR enhance precision in engineered cell therapies.
  • Outpatient CAR-T administration could reduce costs and increase accessibility for Arcellx.

What critics are saying

  • Competition from established CAR-T therapies like Abecma and Carvykti could limit market share.
  • Dependency on Gilead's Kite partnership poses risks if partnership dynamics change.
  • Phase 3 iMMagine-3 trial delays or failures could impact anito-cel's market timeline.

What makes Arcellx unique

  • Arcellx's CART-ddBCMA has FDA Fast Track and Orphan Drug designations.
  • The novel D-Domain binder in anito-cel enhances antigen binding and cell killing.
  • ARC-SparX offers dosable and controllable CAR-T therapy options.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Unlimited Paid Time Off

Flexible Work Hours

401(k) Company Match

Fully-Paid Parental Leave

Tuition Reimbursement

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

0%

2 year growth

3%
Business Wire
May 9th, 2024
Arcellx And Kite Continue Momentum With Advances In Anito-Cel Multiple Myeloma Program

REDWOOD CITY, Calif. SANTA MONICA, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder. The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3, which Kite expects to start in the second half of this year. The trial will compare the efficacy and safety of anito-cel randomized against the standard of care (SOC) in patients with relapsed and/or refractory multiple myeloma (rrMM) who have received one to three prior lines of therapy, including an immunomodulatory drug (lMiD) and an anti-CD38 monoclonal antibody

Business Wire
May 9th, 2024
Kite And Arcellx Continue Momentum With Advances In Anito-Cel Multiple Myeloma Program

REDWOOD CITY, Calif. SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder. The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3, which Kite expects to start in the second half of this year. The trial will compare the efficacy and safety of anito-cel randomized against the standard of care (SOC) in patients with relapsed and/or refractory multiple myeloma (rrMM) who have received one to three prior lines of therapy, including an immunomodulatory drug (lMiD) and an anti-CD38 monoclonal antibody

Yahoo Finance
Mar 2nd, 2024
Earnings Update: Arcellx, Inc. (NASDAQ:ACLX) Just Reported And Analysts Are Boosting Their Estimates

Arcellx, Inc. (NASDAQ:ACLX) just released its full-year report and things are looking bullish.

PRWeek
Feb 7th, 2024
PR Week Global

Biotech Arcellx promotes Myesha Lacy to chief investor and comms officer | PR Week

Zacks Investment Research
Dec 15th, 2023
Gilead (GILD) Outperforms Industry in 6 Months: What Lies Ahead?

The partnership with Arcellx was recently expanded to develop CART-ddBCMA to treat lymphomas.